Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 0062 • ACR Convergence 2022
Comparing Alzheimer’s Disease Risk in Patients with Chronic Inflammatory Autoimmune Diseases: A Medicare Cohort Study
Justin Levinson¹, Jonathan Katz², Yi Chen³, W. Ryan Powell⁴, Andrea Gilmore-Bykovskyi⁵, Amy J. Kind⁶ and Christie Bartels⁷, ¹University of Wisconsin School of Medicine and Public Health, Department of Medicine, Rheumatology Division, Madison, WI, ²University of Wisconsin Hospitals and Clinics, Madison, WI, ³University of Wisconsin School of Medicine and Public Health, Department of Medicine, Department of Biostatistics and Informatics, Madison, WI, ⁴University of Wisconsin School of Medicine and Public Health, Center for Health Disparities Research, Thousand Oaks, CA, ⁵University of Wisconsin School of Medicine and Public Health, Department of Emergency Medicine; and the Center for Health Disparities Research, Madison, WI, ⁶University of Wisconsin School of Medicine and Public Health, Department of Medicine, Geriatrics Division & Center for Health Disparities Research, Madison, WI, ⁷University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Chronic inflammatory diseases have been associated with an increased risk of Alzheimer’s disease (AD), yet emerging research in rheumatoid arthritis (RA) and psoriasis suggests…
Abstract Number: 0115 • ACR Convergence 2022
Facilitators of Immunosuppressive Medication Adherence in Systemic Lupus Erythematosus: A Qualitative Study of Racial Minority Patients, Lupus Providers and Clinic Staff
Shannon Herndon¹, Amy Corneli², Carrie Dombeck³, Teresa Swezey³, Megan Clowse³, Jennifer Rogers⁴, Lisa Criscione-Schreiber², Rebecca Sadun³, Jayanth Doss³, Amanda Eudy⁵, Hayden Bosworth² and Kai Sun³, ¹Duke University Hospital, Durham, NC, ²Duke University School of Medicine, Durham, NC, ³Duke University, Durham, NC, ⁴Duke, Durham, NC, ⁵Duke University, Raleigh, NC
Background/Purpose: SLE disproportionately affects patients of color. Medication nonadherence is more common among patients of color with SLE and is associated with worse health outcomes.…
Abstract Number: 0328 • ACR Convergence 2022
Predicting Progression from Undifferentiated to Definitive Connective Tissue Diseases: A Systematic Review and Meta-analysis
Sarah Dyball¹, Mia Rodziewicz¹, Claudia Mendoza Pinto², Ian N. Bruce³ and Ben Parker⁴, ¹The University of Manchester, Manchester, United Kingdom, ²Systemic Autoimmune Diseases Research Unit, High-Specialty Medical Unit-CIBIOR, Mexican Social Security Institute, Puebla, Mexico, ³Centre for Epidemiology Versus Arthritis, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom, ⁴Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom
Background/Purpose: Undifferentiated connective tissue disease (UCTD) encapsulates a broad range of conditions including incomplete forms of systemic lupus erythematosus (SLE) and systemic sclerosis (SSc), some…
Abstract Number: 0346 • ACR Convergence 2022
Improving Eye Screening Compliance in Patients Taking Hydroxychloroquine in a Community Hospital Setting
George Gennaoui¹, Sana Kang² and J. Patricia Dhar³, ¹Ascension St. John Hospital, St. Clair Shores, MI, ²Ascension St John Hospital, Chesterfield, MO, ³Ascension St. John Hospital and Wayne State University School of Medicine, Bloomfield Hills, MI
Background/Purpose: Hydroxychloroquine (HCQ) is a medication used in most patients with systematic lupus erythematous (SLE). It is generally a safe; however, it can cause retinal…
Abstract Number: 0368 • ACR Convergence 2022
Which Are the Best Therapeutic Strategies for Systemic Lupus Erythematosus Severe Thrombocytopenia? A Ten Year Analysis
Erik Cimé-Aké, Ana Barrera-Vargas, Roberta Demichelis-Gómez, Martha Ramírez-Alemón and Marina Rull-Gabayet, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico
Background/Purpose: Severe thrombocytopenia in systemic lupus erythematosus (SLE) is characterized by poor response to glucocorticoids and frequent relapses. Information regarding the risk of relapse with…
Abstract Number: 0633 • ACR Convergence 2022
Identification of Systemic Lupus Erythematosus Endotypes by Analysis of Inflammatory and Immunologic Gene Expression Signatures
Erika Hubbard¹, Prathyusha Bachali², Kathryn Kingsmore Allison¹, Yisha He¹, Michelle Catalina³, Amrie Grammer⁴ and Peter Lipsky¹, ¹AMPEL BioSolutions, Charlottesville, VA, ²AMPEL BioSolutions, Redmond, WA, ³AMPEL BioSolutions, Harvard, MA, ⁴AMPEL LLC, Charlottesville, VA
Background/Purpose: One of the hallmarks of SLE is clinical and molecular heterogeneity. Recent work has leveraged next-generation sequencing techniques to identify molecular signatures characteristic of…
Abstract Number: 0653 • ACR Convergence 2022
JAK Inhibitors Counteract Cellular Toxicity of Hydroxychloroquine in Vitro
Hiroshi Kajiyama¹, Yoshimi Aizaki², Hiroaki Yazawa³, Kazuhiro Yokota³, Yasuto Araki², Yuji Akiyama² and Toshihide Mimura⁴, ¹Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Yokohama, Japan, ²Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Iruma Saitama, Japan, ³Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Iruma Saitama, ⁴Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan
Background/Purpose: Hydroxychloroquine (HCQ) is an anti-malarial medicine and an immunomodulator to treat autoimmune diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Clinical…
Abstract Number: 0674 • ACR Convergence 2022
Prevalence of Heparin Induced Thrombocytopenia in Hospitalized Patients with Antiphospholipid Syndrome or Systemic Lupus Erythematosus with Antiphospholipid Antibodies
Vincent Tran, Amy Schmitt and Shanthini Kasturi, Tufts Medical Center, Boston, MA
Background/Purpose: Thrombosis and thrombocytopenia are defining characteristics of antiphospholipid syndrome (APS), but can also be seen in heparin-induced thrombocytopenia (HIT). Hospitalized patients with APS are…
Abstract Number: 0957 • ACR Convergence 2022
Timeliness of Fetal Echocardiography for Congenital Heart Block Detection in Anti-Ro/La-Positive Pregnancies
Amanda Ohayon¹, Nikola Wilk¹, Arielle Mendel², Mayssa Moukarzel¹, Jessica Simoneau¹, Wadi Mawad¹, Gabriel Altit¹ and Evelyne Vinet², ¹McGill University Health Center, Montréal, QC, Canada, ²McGill University Health Centre, Montréal, QC, Canada
Background/Purpose: Best practice guidelines recommend screening for congenital heart block (CHB) in anti-Ro/La-positive pregnancies with serial echocardiography starting between 16 to 18 weeks of gestational…
Abstract Number: 0978 • ACR Convergence 2022
Belimumab After Rituximab Targets IgA2 Anti-dsDNA Antibody Production and Shifts Repopulating B-cells Towards an Anergic, Non-pathogenic Phenotype in Systemic Lupus Erythematosus
Muhammad Shipa¹, liliana ribeiro santos², Dao X Nguyen¹, Andrew Embleton-Thirsk¹, Mariea parvaz¹, David Isenberg¹, Caroline Gordon³ and Michael Ehrenstein¹, ¹University College London, London, United Kingdom, ²University College London, London, ³Rheumatology Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom
Background/Purpose: The results from the BEAT-lupus trial comparing belimumab vs placebo, both after rituximab in systemic lupus erythematosus (SLE) have recently been reported (1). We…
Abstract Number: 0995 • ACR Convergence 2022
Association of Glucocorticoid Use with Healthcare Utilization Among Persons with Systemic Lupus Erythematosus
Patricia Katz¹, Sofia Pedro², Jiyoon Choi³ and Kaleb Michaud⁴, ¹UCSF, San Rafael, CA, ²Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ³Bristol Myers Squibb, Lawrenceville, NJ, ⁴University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Glucocorticoids (GCs) have long been a mainstay of treatment for systemic lupus erythematosus (SLE). While GCs do provide benefit, there are potential side effects…
Abstract Number: 1136 • ACR Convergence 2022
Stratification of Systemic Lupus Erythematosus (SLE) Patients Based on the Molecular Patterns of Mouse Models
Maria Rivas Torrubia, Maria Morell, Marta Alarcon-Riquelme and Guillermo Barturen, Center for Genomics and Oncological Research (GENYO), Granada, Spain
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune, chronic and multisystemic autoimmune disorder, which typically affects women and presents high severity and mortality. It is…
Abstract Number: 1337 • ACR Convergence 2022
Dietary Mineral Intake of an Inner-City Population and Its Impact on Disease Activity in Patients with SLE
Paolo Pio Tempongko, Eugenio Capitle, Steven Keller and Reena Khianey, Rutgers University - New Jersey Medical School, Newark, NJ
Background/Purpose: Many patients implement a complementary dietary approach in addition to conventional pharmacologic therapy for systemic lupus erythematosus (SLE). There is growing evidence that several…
Abstract Number: 1440 • ACR Convergence 2022
Interrelation of T-cell Cytokines and Autoantibodies in Lupus Nephritis: A Cross-sectional Study
Fatima Alduraibi¹, Kathryn Sullivan¹, Winn Walter Chatham², Hui-Chen Hsu¹ and John Mountz¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Clinical Immunology and Rheumatology, Birmingham, AL
Background/Purpose: To determine if different classes of lupus nephritis (LN) are correlated with specific circulating autoantibodies (autoAbs) and T-helper cell cytokines and other manifestations of…
Abstract Number: 1456 • ACR Convergence 2022
Latin-American Systemic Lupus Erythematosus Clusters
Rosana Quintana¹, Romina Nieto², Marina Scolnik³, Nidia Meras⁴, Cintia Otaduy⁵, María Emilia Sattler⁶, Luciana González Lucero⁷, Nicolas Perez⁸, Ana Silva⁹, Odirlei Monticielo¹⁰, Angela Luzia B Duarte¹¹, Edgard Reis Neto¹², Milena Mimica¹³, Gustavo Aroca Martinez¹⁴, Gerardo Quintana-Lopez¹⁵, Mario Moreno Alvarez¹⁶, Miguel Angel Saavedra Salinas¹⁷, Margarita Portela¹⁸, Luis H Silveira¹⁹, Ignacio García Valladares²⁰, Carlos Abud-Mendoza²¹, Jorge Esquivel-Valerio²², Maria Duarte²³, Roberto Muñoz Louis²⁴, Vicente Juárez²⁵, Eduardo Ferreira Borba Neto²⁶, Luis Catoggio²⁷, Graciela Alarcón²⁸, Jose Puerta²⁹, Guillermina Harvey³⁰, Elisa Novati³¹, Valeria Arturi³², Wilfredo Grageda³³, Cecilia Pisoni³⁴, Francinne Machado Riobeiro³⁵, Emily Figueiredo Neves Yuki²⁶, Iris Guerra Herrera³⁶, Gabriel Tobón³⁷, Andres Cadena Bonfanti¹⁴, Hilda Fragoso-Loyo³⁸, Marie Teresa de Martinez³⁹, Claudia Selene Mora Trujillo⁴⁰, Manuel Ugarte-Gil⁴¹, Ernesto Zavala Flores⁴², Ricardo Robaina⁴³, Gonzalo Silveira⁴⁴, Federico Zazzetti⁴⁵, Ashley Orillion⁴⁶, Guillermo Pons-Estel⁴⁷, Bernardo Pons-Estel² and Urbano Sbarigia⁴⁸, ¹Grupo Oroño - Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Santa Fe, Argentina, ²Grupo Oroño - Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, ³Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁴Hospital Italiano de Córdoba, Cordoba, Argentina, ⁵Hospital Córdoba, Córdoba, Argentina, ⁶Sanatorio Británico, Paraná, Argentina, ⁷Hospital Padilla, San Miguel de Tucumán, Argentina, ⁸Instituto Lanari, Buenos Aires, Argentina, ⁹Hospital das Clinicas, Univerisad Federal de Goias, Goiania, Brazil, ¹⁰Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil, ¹¹Universidade Federal de Pernambuco, Recife, Brazil, ¹²Universidad Federal São Paulo, São Paulo, Brazil, ¹³Universidad San Sebastián, Santiago, Chile, ¹⁴Clínica de la Costa Ltda., Barranquilla, Colombia, ¹⁵Reumavance Group, Rheumatology section, Department of Internal Medicine, Fundación Santa Fe de Bogotá University Hospital. Bogota, Colombia; Department of Internal Medicine, School of Medicine, Universidad Nacional de Colombia. Bogota, Colombia; Department of Internal Medicine. School of Medicine, Universidad de Los Andes, Bogotá, Colombia, ¹⁶Hospital Luis Vernaza, Guayaquil, Ecuador, ¹⁷IMSS, Ciudad de México, Mexico, ¹⁸Centro Médico Nacional Siglo XXI, Ciudad de México, Mexico, ¹⁹Instituto Nacional de Cardiología, Ciudad de México, Mexico, ²⁰CEIBAC, SC, Guadalajara, Mexico, ²¹Hospital Central and Faculty of Medicine, UASLP, San Luis Potosí, Mexico, ²²Hospital Universitario “Dr. José Eleuterio Gonzalez", Monterrey, Mexico, ²³Hospital de Clínicas Paraguay, Asunción, Paraguay, ²⁴Hospital Docente Padre Billini, Santo Domingo, Dominican Republic, ²⁵MSP, Salta, Argentina, ²⁶Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ²⁷Hospital Italiano de Buenos Aires, Olivos, Argentina, ²⁸The University of Alabama at Birmingham, Oakland, ²⁹Rheumatology Department, Hospital Clinic, University of Barcelona, Barcelona, Spain, ³⁰Instituto de Investigaciones Teóricas y Aplicadas. Facultad de Ciencias Económicas y Estadistica. Universidad Nacional de Rosario, Santa Fe, Argentina, ³¹Hospital Privado Universitario de Córdoba, Cordoba, Argentina, ³²Hospital HIGA San Martín, Buenos Aires, Argentina, ³³Hospital General de Agudos J.M. Ramos Mejía, Buenos Aires, Argentina, ³⁴CEMIC- Centro de Educación Médica e Investigaciones Clínicas, Buenos Aires, Argentina, ³⁵Hospital Universitario Pedro Ernesto, UERJ, Rio de Janiero, Brazil, ³⁶Hospital del Salvador, Santiago, Chile, ³⁷Fundación Valle del Lili, Calí, Colombia, ³⁸Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico, ³⁹Hospital de Clínicas I, Montevideo, Uruguay, ⁴⁰Hospital Nacional Edgardo Rebagliatti Martins, Lima, Peru, ⁴¹Hospital Nacional Guillermo Almenara Irigoyen, Lima, Peru, ⁴²Hospital Cayetano Heredia, San Martín de Porres Distric, Peru, ⁴³Clínica Médica C, Hospital de Clínicas, UDELAR, Montevideo, Uruguay, ⁴⁴Grupo de Investigacion de EAIS y Reumatológicas, A Coruña, Spain, ⁴⁵Janssen Medical Affairs Global Services, LLC, Buenos Aires, Argentina, ⁴⁶Janssen, Horsham, PA, ⁴⁷CREAR, Rosario, Argentina, ⁴⁸Johnson & Johnson, Beerse, Belgium
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex and heterogeneous autoimmune disease. The identification of patient subgroups or clusters may be useful for the management…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].